Development of a perfusion process for serum-free adenovirus vector herpes zoster vaccine production

AMB Express

Kai Feng¹  Zhonghu Bai¹  Yang Sun¹  Yupeng Liu¹  Lingling Huang¹  Jianqi Nie² 

[1] Institute of Microbial Engineering, School of Life Sciences, Henan University;The Key Laboratory of Industrial Biotechnology, Ministry of Education, Jiangnan University;

关键词: Herpes zoster vaccine;    Adenovirus vector;    Perfusion;    Serum-free;    Design of experiment.;   

DOI  :  10.1186/s13568-022-01398-7

来源: DOAJ

【 摘 要 】

Abstract Herpes zoster is caused by reactivation of the varicella zoster virus (VZV). Researching and developing a herpes zoster vaccine will help to decrease the incidence of herpes zoster. To increase the bioreactor productivity, a serum-free HEK293 cell perfusion process with adenovirus vector herpes zoster (rAd-HZ) vaccine production was developed efficiently using the design of experiment (DoE) method. First, serum-free media for HEK293 cells were screened in both batch and semi-perfusion culture modes. Then, three optimal media were employed in a medium mixture design to improve cell culture performance, and the 1:1 mixture of HEK293 medium and MCD293 medium (named HM293 medium) was identified as the optimal formulation. On the basis of the HM293 medium, the relationship of critical process parameters (CPPs), including the time of infection (TOI), multiplicity of infection (MOI), pH, and critical quality attributes (CQAs) (adenovirus titer (Titer), cell-specific virus yield (CSVY), adenovirus fold expansion (Fold)) of rAd-HZ production was investigated using the DoE approach. Furthermore, the robust setpoint and design space of these CPPs were explored. Finally, the rAd-HZ production process with parameters at a robust setpoint (TOI = 7.2 × 106 cells/mL, MOI = 3.7, and pH = 7.17) was successfully scaled-up to a 3-L bioreactor with an alternating tangential flow system, yielding an adenovirus titer of 3.0 × 1010 IFU/mL, a CSVY of 4167 IFU/cells, a Fold of 1117 at 2 days post infection (dpi). The DoE approach accelerated the development of a HEK293 serum-free medium and of a robust adenovirus production process.

【 授权许可】

Unknown